研究发现：血浆磷酸化tau181蛋白可用于预测阿尔茨海默氏症
瑞典隆德大学Oskar Hansson、Shorena Janelidze等研究人员合作揭示，血浆磷酸化tau181（P-tau181）蛋白与阿尔茨海默氏症（AD）的关联性。相关论文于2020年3月2日在线发表于《自然—医学》。
研究人员在三个队列中研究了血浆P-tau181，共有589名个体，包括无认知障碍的参与者以及轻度认知障碍（MCI）、AD痴呆和非AD神经退行性疾病的患者。
血浆P-tau181在临床前AD中升高，在MCI和痴呆期进一步升高。它与CSF P-tau181相关，并预测出阳性Tau正电子发射断层扫描（PET）（曲线下面积（AUC）= 0.87–0.91，不同的大脑区域）。
血浆P-tau181将AD痴呆症与非AD神经退行性疾病区别开来，其准确性与Tau PET和CSF P-tau181相似（AUC = 0.94-0.98），并在尸检证实的队列中检测到AD神经病理学。血浆高P-tau181与认知障碍者和MCI患者AD痴呆症的发展有关。
总之，血浆P-tau181是AD的一种非侵入性诊断和预后生物标志物，可能在临床实践和试验中有用。
据悉，血浆P-tau181蛋白在AD中可能增加，但其在鉴别诊断和预后方面的用途尚不清楚。
附：英文原文
Title: Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Author: Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, Ruben Smith, Thomas G. Beach, Geidy E. Serrano, Xiyun Chai, Nicholas K. Proctor, Udo Eichenlaub, Henrik Zetterberg, Kaj Blennow, Eric M. Reiman, Erik Stomrud, Jeffrey L. Dage, Oskar Hansson
Issue&Volume: 2020-03-02
Abstract: Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC)=0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC=0.94–0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.
DOI: 10.1038/s41591-020-0755-1
Source: https://www.nature.com/articles/s41591-020-0755-1
声明：本文版权归原作者所有，转载文章仅为传播更多信息，如作者信息标记有误，或侵犯您的版权，请联系我们，我们将在及时修改或删除内容，联系邮箱：marketing@360worldcare.com
